Aro Biotherapeutics
is a Pennsylvania-based biotechnology company that researches and develops centyrin-based therapies for the treatment of autoimmune diseases... Read moreAro Biotherapeutics
is a Pennsylvania-based biotechnology company that researches and develops centyrin-based therapies for the treatment of autoimmune diseases... Read more
News
Sep 24, 2025
StreetInsider
Press Release: Aro Biotherapeutics : Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD)
Mar 19, 2025
Boston Real Estate Times
Aro Biotherapeutics: Aro Biotherapeutics CEO Purnanand Sarma to Speak at Boston Life Sciences, Biotech, Pharma, and Medical Facilities Conference
Feb 11, 2025
The Business Journals: Philadelphia
Aro Biotherapeutics: Philadelphia biotech firm backed by more than $130M names new CEO
Feb 10, 2025
Benzinga
Aro Biotherapeutics: Aro Biotherapeutics Appoints President And CE...
Jan 23, 2025
Clinical Trials Arena
Aro Biotherapeutics: First patient dosed in Phase Ib Pompe disease trial
Oct 29, 2024
Business Wire
Press Release: Aro Biotherapeutics : Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD)
Feb 06, 2024
Business Wire
Press Release: Aro Biotherapeutics : Aro Biotherapeutics to Present Updates on ABX1100, a CD71 Centyrin - Gys1 siRNA Conjugate for the Treatment of Pompe Disease at the 20th Annual WORLD Symposium 2024 Meeting
Dec 03, 2023
Pulse2.0
Aro Biotherapeutics: Aro Biotherapeutics: $41.5 Million Secured To Pioneer Tissue-Targeted Genetic Medicines
Nov 29, 2023
Pharamceutical Technology
Aro Biotherapeutics: Aro Biotherapeutics raises funds for Pompe disease treatment
Nov 29, 2023
The Business Journals
Aro Biotherapeutics: Aro Biotherapeutics raises $41.5M from investors in its second multimillion-dollar financing of 2023
Aro Biotherapeutics Competitors
1
2
3
4
5
6
7
8
9
10